Wet Age-Related Macular Degeneration (AMD) Market by Product (Lucentis, Eylea, Avastin), by Distribution Channel (Direct, Indirect), by Age Group (Above 80 Years, 60–80 Years, 40–59 Years), by Route of Administration (Intravitreal, Intravenous), by End User (Hospitals & Clinics, Research & Academic Institutes), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, Russia, Sweden, Norway, Belgium, Switzerland, Austria, China, Japan, India, South Korea, Malaysia, Thailand, Australia, Singapore, Brazil, Mexico, Argentina, Colombia, Israel, South Africa, Saudi Arabia) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2014–2024

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Product

1.3.2 Market Segmentation by Distribution Channel

1.3.3 Market Segmentation by Age Group

1.3.4 Market Segmentation by Route of Administration

1.3.5 Market Segmentation by End User

1.3.6 Market Segmentation by Geography

1.3.7 Analysis Period

1.3.8 Market Data Reporting Unit

1.3.8.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Product

4.1.1.1 Lucentis

4.1.1.2 Eylea

4.1.1.3 Avastin

4.1.1.4 Others

4.1.2 By Distribution Channel

4.1.2.1 Direct

4.1.2.2 Indirect

4.1.3 By Age Group

4.1.3.1 Above 80 years

4.1.3.2 60–80 years

4.1.3.3 40–59 years

4.1.4 By Route of Administration

4.1.4.1 Intravitreal

4.1.4.2 Intravenous

4.1.5 By End User

4.1.5.1 Hospitals and clinics

4.1.5.2 Research and academic institutes

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Positive clinical trial results and increasing approvals for pipeline drugs

4.2.1.2 Growing number of acquisitions and collaborations

4.2.2 Drivers

4.2.2.1 Increasing prevalence of AMD

4.2.2.2 Lack of availability of specific treatment

4.2.2.3 Surge in geriatric population

4.2.2.4 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Increasing usage of off-label drugs

4.2.3.2 High cost of drugs and lack of insurance coverage

4.2.3.3 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Emerging market for wet AMD in APAC

4.2.4.2 Prospective alternative therapies

4.3 Porter’s Five Forces Analysis

4.4 Epidemiology Overview

4.5 Pipeline Drugs for Wet AMD

4.6 Pricing and Reimbursement Scenario

4.6.1 Pricing

4.6.2 Reimbursement

Chapter 5. Global Market Size and Forecast

5.1 By Product

5.2 By Distribution Channel

5.3 By Age Group

5.4 By Route of Administration

5.5 By End User

5.6 By Region

Chapter 6. North America Market Size and Forecast

6.1 By Product

6.2 By Distribution Channel

6.3 By Age Group

6.4 By Route of Administration

6.5 By End User

6.6 By Country

Chapter 7. Europe Market Size and Forecast

7.1 By Product

7.2 By Distribution Channel

7.3 By Age Group

7.4 By Route of Administration

7.5 By End User

7.6 By Country

Chapter 8. APAC Market Size and Forecast

8.1 By Product

8.2 By Distribution Channel

8.3 By Age Group

8.4 By Route of Administration

8.5 By End User

8.6 By Country

Chapter 9. LATAM Market Size and Forecast

9.1 By Product

9.2 By Distribution Channel

9.3 By Age Group

9.4 By Route of Administration

9.5 By End User

9.6 By Country

Chapter 10. MEA Market Size and Forecast

10.1 By Product

10.2 By Distribution Channel

10.3 By Age Group

10.4 By Route of Administration

10.5 By End User

10.6 By Country

Chapter 11. Global Strategic Developments

11.1 Clinical Trial Approvals and Results

11.2 Acquisitions and Collaborations

Chapter 12. Company Profiles

12.1 Regeneron Pharmaceuticals Inc.

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.1.3 Key Financial Summary

12.1.4 SWOT Analysis

12.2 Neurotech Pharmaceuticals Inc.

12.2.1 Business Overview

12.2.2 Product and Service Offerings

12.3 Ophthotech Corporation

12.3.1 Business Overview

12.3.2 Product and Service Offerings

12.3.3 Key Financial Summary

12.4 Kubota Pharmaceutical Holdings Co. Ltd.

12.4.1 Business Overview

12.4.2 Product and Service Offerings

12.4.3 Key Financial Summary

12.5 Alimera Sciences Inc.

12.5.1 Business Overview

12.5.2 Product and Service Offerings

12.5.3 Key Financial Summary

12.5.4 SWOT Analysis

12.6 Adverum Biotechnologies Inc.

12.6.1 Business Overview

12.6.2 Product and Service Offerings

12.7 Gilead Sciences Inc.

12.7.1 Business Overview

12.7.2 Product and Service Offerings

12.7.2.1 Marketed products

12.7.2.2 Pipeline products

12.7.3 Key Financial Summary

12.7.4 SWOT Analysis

12.8 Apellis Pharmeceuticals Inc.

12.8.1 Business Overview

12.8.2 Product and Service Offerings

12.9 Novartis AG

12.9.1 Business Overview

12.9.2 Product and Service Offerings

12.9.2.1 Marketed products

12.9.2.2 Pipeline products

12.9.3 Key Financial Summary

12.10 Pfizer Inc.

12.10.1 Business Overview

12.10.2 Product and Service Offerings

12.10.2.1 Marketed products

12.10.2.2 Pipeline products

12.10.3 Key Financial Summary

12.11 GlaxoSmithKline plc

12.11.1 Business Overview

12.11.2 Product and Service Offerings

12.11.2.1 Marketed products

12.11.2.2 Pipeline products

12.11.3 Key Financial Summary

12.12 Bayer AG

12.12.1 Business Overview

12.12.2 Product and Service Offerings

12.12.3 Key Financial Summary

12.13 F. Hoffmann-La Roche Ltd.

12.13.1 Business Overview

12.13.2 Product and Service Offerings

12.13.3 Key Financial Summary

12.14 Allergan plc

12.14.1 Business Overview

12.14.2 Product and Service Offerings

12.14.3 Key Financial Summary

12.15 Bausch Health Companies Inc.

12.15.1 Business Overview

12.15.2 Product and Service Offerings

12.15.3 Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

List of Tables

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 LIST OF PHASE III DRUGS

TABLE 5 LIST OF PHASE II DRUGS

TABLE 6 LIST OF PHASE I DRUGS

TABLE 7 LIST OF PRE-CLINICAL DRUGS

TABLE 8 COST COMPARISON OF ANTI-VEGF THERAPIES FOR MCNV

TABLE 9 REIMBURSEMENT RATES OF LUCENTIS AND EYLEA PER UNIT DOSE

TABLE 10 GLOBAL WET AMD MARKET, BY PRODUCT, $M (2019–2024)

TABLE 11 GLOBAL WET AMD MARKET, BY PRODUCT, $M (2025–2030)

TABLE 12 GLOBAL WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 13 GLOBAL WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 14 GLOBAL WET AMD MARKET, BY AGE GROUP, $M (2019–2024)

TABLE 15 GLOBAL WET AMD MARKET, BY AGE GROUP, $M (2025–2030)

TABLE 16 GLOBAL WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2024)

TABLE 17 GLOBAL WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2025–2030)

TABLE 18 GLOBAL WET AMD MARKET, BY END USER, $M (2019–2024)

TABLE 19 GLOBAL WET AMD MARKET, BY END USER, $M (2025–2030)

TABLE 20 GLOBAL WET AMD MARKET, BY REGION, $M (2019–2024)

TABLE 21 GLOBAL WET AMD MARKET, BY REGION, $M (2025–2030)

TABLE 22 NORTH AMERICA WET AMD MARKET, BY PRODUCT, $M (2019–2024)

TABLE 23 NORTH AMERICA WET AMD MARKET, BY PRODUCT, $M (2025–2030)

TABLE 24 NORTH AMERICA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 25 NORTH AMERICA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 26 NORTH AMERICA WET AMD MARKET, BY AGE GROUP, $M (2019–2024)

TABLE 27 NORTH AMERICA WET AMD MARKET, BY AGE GROUP, $M (2025–2030)

TABLE 28 NORTH AMERICA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2024)

TABLE 29 NORTH AMERICA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2025–2030)

TABLE 30 NORTH AMERICA WET AMD MARKET, BY END USER, $M (2019–2024)

TABLE 31 NORTH AMERICA WET AMD MARKET, BY END USER, $M (2025–2030)

TABLE 32 NORTH AMERICA WET AMD MARKET, BY COUNTRY, $M (2019–2024)

TABLE 33 NORTH AMERICA WET AMD MARKET, BY COUNTRY, $M (2025–2030)

TABLE 34 EUROPE WET AMD MARKET, BY PRODUCT, $M (2019–2024)

TABLE 35 EUROPE WET AMD MARKET, BY PRODUCT, $M (2025–2030)

TABLE 36 EUROPE WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 37 EUROPE WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 38 EUROPE WET AMD MARKET, BY AGE GROUP, $M (2019–2024)

TABLE 39 EUROPE WET AMD MARKET, BY AGE GROUP, $M (2025–2030)

TABLE 40 EUROPE WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2024)

TABLE 41 EUROPE WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2025–2030)

TABLE 42 EUROPE WET AMD MARKET, BY END USER, $M (2019–2024)

TABLE 43 EUROPE WET AMD MARKET, BY END USER, $M (2025–2030)

TABLE 44 EUROPE WET AMD MARKET, BY COUNTRY, $M (2019–2024)

TABLE 45 EUROPE WET AMD MARKET, BY COUNTRY, $M (2025–2030)

TABLE 46 APAC WET AMD MARKET, BY PRODUCT, $M (2019–2024)

TABLE 47 APAC WET AMD MARKET, BY PRODUCT, $M (2025–2030)

TABLE 48 APAC WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 49 APAC WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 50 APAC WET AMD MARKET, BY AGE GROUP, $M (2019–2024)

TABLE 51 APAC WET AMD MARKET, BY AGE GROUP, $M (2025–2030)

TABLE 52 APAC WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2024)

TABLE 53 APAC WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2025–2030)

TABLE 54 APAC WET AMD MARKET, BY END USER, $M (2019–2024)

TABLE 55 APAC WET AMD MARKET, BY END USER, $M (2025–2030)

TABLE 56 APAC WET AMD MARKET, BY COUNTRY, $M (2019–2024)

TABLE 57 APAC WET AMD MARKET, BY COUNTRY, $M (2025–2030)

TABLE 58 LATAM WET AMD MARKET, BY PRODUCT, $M (2019–2024)

TABLE 59 LATAM WET AMD MARKET, BY PRODUCT, $M (2025–2030)

TABLE 60 LATAM WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 61 LATAM WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 62 LATAM WET AMD MARKET, BY AGE GROUP, $M (2019–2024)

TABLE 63 LATAM WET AMD MARKET, BY AGE GROUP, $M (2025–2030)

TABLE 64 LATAM WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2024)

TABLE 65 LATAM WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2025–2030)

TABLE 66 LATAM WET AMD MARKET, BY END USER, $M (2019–2024)

TABLE 67 LATAM WET AMD MARKET, BY END USER, $M (2025–2030)

TABLE 68 LATAM WET AMD MARKET, BY COUNTRY, $M (2019–2024)

TABLE 69 LATAM WET AMD MARKET, BY COUNTRY, $M (2025–2030)

TABLE 70 MEA WET AMD MARKET, BY PRODUCT, $M (2019–2024)

TABLE 71 MEA WET AMD MARKET, BY PRODUCT, $M (2025–2030)

TABLE 72 MEA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 73 MEA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 74 MEA WET AMD MARKET, BY AGE GROUP, $M (2019–2024)

TABLE 75 MEA WET AMD MARKET, BY AGE GROUP, $M (2025–2030)

TABLE 76 MEA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2024)

TABLE 77 MEA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2025–2030)

TABLE 78 MEA WET AMD MARKET, BY END USER, $M (2019–2024)

TABLE 79 MEA WET AMD MARKET, BY END USER, $M (2025–2030)

TABLE 80 MEA WET AMD MARKET, BY COUNTRY, $M (2019–2024)

TABLE 81 MEA WET AMD MARKET, BY COUNTRY, $M (2025–2030)

TABLE 82 REGENERON PHARMACEUTICALS INC. – AT A GLANCE

TABLE 83 REGENERON PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY

TABLE 84 NEUROTECH PHARMACEUTICALS INC. – AT A GLANCE

TABLE 86 OPHTHOTECH CORPORTION – KEY FINANCIAL SUMMARY

TABLE 88 KUBOTA PHARMACEUTICAL HOLDINGS CO. LTD. – KEY FINANCIAL SUMMARY

TABLE 90 ALIMERA SCIENCES INC. – KEY FINANCIAL SUMMARY

TABLE 92 GILEAD SCIENCES INC. – AT A GLANCE

TABLE 93 GILEAD SCIENCES INC. – KEY FINANCIAL SUMMARY

TABLE 95 NOVARTIS AG – AT A GLANCE

TABLE 96 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 97 PFIZER INC. – AT A GLANCE

TABLE 98 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 99 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 100 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY

TABLE 101 BAYER AG – AT A GLANCE

TABLE 102 BAYER AG – KEY FINANCIAL SUMMARY

TABLE 103 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 104 PRODUCT UNDER DEVELOPMENT

TABLE 105 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 106 ALLERGAN PLC – AT A GLANCE

TABLE 107 ALLERGAN PLC – KEY FINANCIAL SUMMARY

TABLE 108 BAUSCH HEALTH COMPANIES INC. – AT A GLANCE

TABLE 109 BAUSCH HEALTH COMPANIES INC. – KEY FINANCIAL SUMMARY

 

List of Figures

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 7 DATA TRIANGULATION APPROACH

FIG 8 GLOBAL WET AMD MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 INTENSITY OF RIVALRY

FIG 12 THREAT OF NEW ENTRANTS

FIG 13 THREAT OF SUBSTITUTES

FIG 14 SNAPSHOT OF GLOBAL WET AMD MARKET (2023)

FIG 15 GLOBAL WET AMD MARKET, BY PRODUCT, $M (2019–2030)

FIG 16 GLOBAL WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2030)

FIG 17 GLOBAL WET AMD MARKET, BY AGE GROUP, $M (2019–2030)

FIG 18 GLOBAL WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 19 GLOBAL WET AMD MARKET, BY END USER, $M (2019–2030)

FIG 20 MAJOR MARKETS FOR WET AMD DRUGS

FIG 21 NORTH AMERICA WET AMD MARKET SNAPSHOT

FIG 22 NORTH AMERICA WET AMD MARKET, BY PRODUCT, $M (2019–2030)

FIG 23 NORTH AMERICA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2030)

FIG 24 NORTH AMERICA WET AMD MARKET, BY AGE GROUP, $M (2019–2030)

FIG 25 NORTH AMERICA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 26 NORTH AMERICA WET AMD MARKET, BY END USER, $M (2019–2030)

FIG 27 NORTH AMERICA WET AMD MARKET, BY COUNTRY, $M (2019–2030)

FIG 28 EUROPE WET AMD MARKET SNAPSHOT

FIG 29 EUROPE WET AMD MARKET, BY PRODUCT, $M (2019–2030)

FIG 30 EUROPE WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2030)

FIG 31 EUROPE WET AMD MARKET, BY AGE GROUP, $M (2019–2030)

FIG 32 EUROPE WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 33 EUROPE WET AMD MARKET, BY END USER, $M (2019–2030)

FIG 34 EUROPE WET AMD MARKET, BY COUNTRY, $M (2019–2030)

FIG 35 APAC WET AMD MARKET SNAPSHOT

FIG 36 APAC WET AMD MARKET, BY PRODUCT, $M (2019–2030)

FIG 37 APAC WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2030)

FIG 38 APAC WET AMD MARKET, BY AGE GROUP, $M (2019–2030)

FIG 39 APAC WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 40 APAC WET AMD MARKET, BY END USER, $M (2019–2030)

FIG 41 APAC WET AMD MARKET, BY COUNTRY, $M (2019–2030)

FIG 42 LATAM WET AMD MARKET SNAPSHOT

FIG 43 LATAM WET AMD MARKET, BY PRODUCT, $M (2019–2030)

FIG 44 LATAM WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2030)

FIG 45 LATAM WET AMD MARKET, BY AGE GROUP, $M (2019–2030)

FIG 46 LATAM WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 47 LATAM WET AMD MARKET, BY END USER, $M (2019–2030)

FIG 48 LATAM WET AMD MARKET, BY COUNTRY, $M (2019–2030)

FIG 49 MEA WET AMD MARKET SNAPSHOT

FIG 50 MEA WET AMD MARKET, BY PRODUCT, $M (2019–2030)

FIG 51 MEA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2030)

FIG 52 MEA WET AMD MARKET, BY AGE GROUP, $M (2019–2030)

FIG 53 MEA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019–2030)

FIG 54 MEA WET AMD MARKET, BY END USER, $M (2019–2030)

FIG 55 MEA WET AMD MARKET, BY COUNTRY, $M (2019–2030)

FIG 56 REGENERON PHARMACEUTICALS INC. – REVENUE SPLIT BY MARKETED PRODUCT (2023)

FIG 57 ALIMERA SCIENCES INC. – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 58 GILEAD SCIENCES INC. – REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2023)

FIG 59 NOVARTIS AG – REVENUE SPLIT BY MARKETED PRODUCT AND GEOGRAPHY (2023)

FIG 60 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 61 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 62 BAYER AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 63 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2023)

FIG 64 ALLERGAN PLC – REVENUE SPLIT BY SEGMENT (2023)

FIG 65 BAUSCH HEALTH COMPANIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)